Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
|Articles|August 1, 2021

BioPharm International

  • BioPharm International, August 2021 Issue
  • Volume 34
  • Issue 8

Syringe Inspection Line

Syntegon's Syringe Inspection Line utilizes an AI vision system for the inspection of syringe flanges, stoppers, and cylinders.

Syntegon’s integrated syringe visual inspection line features a de-nester, a re-nester, and built-in artificial intelligence (AI) functionality for the inspection of syringe flanges, stoppers, and cylinders. The system, which can output up to 18,000 syringes per hour, is based on the company’s AIM5 series.

The AI vision system is designed to increase detection rates and decrease the number of false rejects for highly viscous parenteral solutions with air bubbles. Static Division technology is used to perform the visual particle inspection. A high-voltage leak detection module can be integrated for CCI testing.

Syntegon

Articles in this issue

over 5 years ago

Single-Use Technologies Prove Effective for Viral Vector Process Development

over 5 years ago

Subunit Vaccines and the Fight Against COVID-19

over 5 years ago

Using Picodroplet Technology to Optimize Bispecific Cell Lines

over 5 years ago

Cell Harvesting Sees Benefits from Automated Processes

over 5 years ago

The Evolving Aseptic Processing Landscape

over 5 years ago

Designing Flexible Fill/Finish Facilities

over 5 years ago

Statistical Approaches for Determining Comparability of Biosimilars

over 5 years ago

Packaging for Stability Studies: to Outsource or Not?

over 5 years ago

FDA Prioritizes Vaccine Review and Process Improvements

over 5 years ago

FDA Inspections Back on Track?

Related to this article

View more
The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
Read more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more